Skip to main content
. Author manuscript; available in PMC: 2021 Apr 28.
Published in final edited form as: ACS Nano. 2020 Apr 6;14(4):4255–4264. doi: 10.1021/acsnano.9b09618

Figure 5:

Figure 5:

In vivo properties of 89Zr-TiO2-Tf in Fox Chase SCID beige triple-immunodeficient mice (6 weeks old): (A) small animal PET/CT sagittal projections of images acquired 48 h after drug administration; (B) SUV for selected organs of interest obtained from images acquired 48 h after drug administration; (C) biodistribution of 89Zr-TiO2-Tf, 89Zr-Tf, and 89Zr-oxalate obtained with γ-emissions; (D) biodistribution comparison of Ti in Zr-TiO2-Tf (blue) and 89Zr-TiO2-Tf (red) acquired with ICP-OES 168 h after administration of compounds (60 μg of each), p = 0.08 for bone uptake; (E) TiO2 distribution between the BM and bone matrix acquired with ICP-OES.